Global Leading Market Research Publisher QYResearch announces the release of its latest report “Benchtop TFF System – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Benchtop TFF System market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Benchtop TFF System was estimated to be worth US243millionin2025andisprojectedtoreachUS243millionin2025andisprojectedtoreachUS413 million by 2032, growing at a CAGR of 8.0% from 2026 to 2032. For bioprocess development scientists, protein purification specialists, and pharmaceutical R&D laboratory managers, the core business imperative lies in deploying benchtop tangential flow filtration (TFF) systems that address the critical need for efficient, scalable separation, concentration, and purification of target biomolecules (monoclonal antibodies (mAbs), recombinant proteins, viral vectors (AAV, LV), mRNA, exosomes, polysaccharides) from complex solutions (cell culture supernatant, lysate, fermentation broth) at laboratory to pilot scale (10 mL to 20 L). Benchtop TFF systems utilize tangential flow filtration dynamics (lateral flow across membrane surface, minimizing fouling and concentration polarization) to achieve high recovery, low shear stress (preserving biomolecule activity), adjustable flux, and user-friendly operation. Key components: peristaltic pump (or diaphragm pump), hollow fiber or flat-sheet cassette membrane module (MWCO (molecular weight cutoff) 1-1000 kDa), pressure sensors, retentate and permeate control valves, and integrated control system (touchscreen, data logging). Applications: drug development (protein concentration, buffer exchange (diafiltration), desalting, clarification, cell harvesting, virus concentration), pilot-scale production (process development, scale-down studies, clinical trial material (small batch)), and others (vaccine processing, exosome isolation, nanoparticle purification). Types: semi-automatic (manual control of pressure, flow rate, permeate valve) for R&D, flexibility, low throughput, and fully automatic (pre-programmed recipes, automated backpressure control, critical process parameter (CPP) monitoring, data logging, 21 CFR Part 11 compliance for GMP (Good Manufacturing Practice) pilot production).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/6093246/benchtop-tff-system
The Benchtop TFF System market is segmented as below:
Sartorius
SOLARIS BIOTECH
Repligen
Sterlitech
Optimus Instruments
Tezalon
Bailinke Pharmaceutical Technology (Shanghai) Co., Ltd.
H&E Co., Ltd.
Rongjie Biotechnology (Suzhou) Co., Ltd.
Beijing Huo’ersi Biological Technology Co., Ltd.
Segment by Type
Semi-automatic
Fully Automatic
Segment by Application
Drug Development
Pilot-scale Production
1. Market Drivers: Biologics Pipeline, Process Development, and Scale-Down Studies
Several powerful forces are driving the benchtop TFF system market:
Biologics and gene therapy pipeline expansion – Monoclonal antibodies (mAbs), recombinant proteins, viral vectors (AAV/LV), mRNA vaccines. Process development (PD) labs require benchtop TFF for downstream purification (concentration, diafiltration). FDA approved biologics 50+ per year.
Pharmaceutical process development and scale-up – Scale-down models (10L-100L) for process characterization, design space, robustness studies. Benchtop TFF mimics large-scale manufacturing (same membrane type, linear flow rate).
Cell and gene therapy (CGT) – Allogeneic therapies (MSCs (mesenchymal stem cells), T cells, NK (natural killer)) viral vector clarification and concentration. Exosome isolation (ultracentrifugation alternative).
Recent market data (December 2025): According to Global Info Research analysis, fully automatic benchtop TFF systems dominate with approximately 60% revenue share (pilot-scale GMP, data logging, CPP automation). Semi-automatic 40% share (R&D, process development, flexibility). Drug development (R&D labs) largest application (65% share). Pilot-scale production (clinical trial material, scale-down) 35% share (fastest-growing). North America largest market (45% share) (biotech hubs). Europe 30% share. Asia-Pacific (China, Singapore, South Korea) 20% share (fastest-growing, 10-12% CAGR). Sartorius (Germany), Repligen (US), SOLARIS BIOTECH (Spain), Sterlitech (US), Optimus Instruments (India), Tezalon (India), and Chinese domestic suppliers (Bailinke, H&E, Rongjie, Huo’ersi) gaining share.
2. Product Types and Specifications
| Type | Control | Pressure Control | Data Logging | GMP Compliance | Applications | Price Range | Share |
|---|---|---|---|---|---|---|---|
| Semi-automatic | Manual (valves, pump speed) | Manual restriction (clamp) | Optional external | No | R&D, process dev, small batch | US$5,000-20,000 | ~40% |
| Fully Automatic | Touchscreen PLC (Programmable Logic Controller), recipe programming | Automatic backpressure valve | Integrated, CSV (computer system validation), 21 CFR Part 11 | Yes (optional) | Pilot GMP, clinical material | US$20,000-60,000 | ~60% |
Key specifications: Membrane type (hollow fiber (0.5-5 mm lumen), flat sheet cassette). MWCO (1kDa, 3kDa, 5kDa, 10kDa, 30kDa, 50kDa, 100kDa, 300kDa, 500kDa, 0.1µm, 0.2µm, 0.45µm). Filtration area (50 cm² to 0.5 m²). Pump flow rate (0.1-10 L/min). Pressure range (0-5 bar). Permeate control (automatic valve, balancing). TMP (Transmembrane Pressure) control. Feed, retentate, permeate pressure sensors (digital). Crossflow velocity control. Temperature sensor (optional). Diafiltration (continuous, discontinuous). Connectivity (USB, Ethernet, SCADA). Single-use flow path (optional). CIP (Clean-in-Place) compatible (stainless steel).
Exclusive observation (Global Info Research analysis): Benchtop TFF system market is dominated by Sartorius (Sartoflow Advanced, Slice), Repligen (KrosFlo, XCell ATF), SOLARIS BIOTECH (NEO, Quattro), Sterlitech (CFT, HP4750). Chinese domestic suppliers (Bailinke, H&E, Rongjie, Huo’ersi) lower cost (30-50% less). Fully automatic GMP systems (21 CFR Part 11) required for clinical material production (Phase I/II). Single-use flow paths (pre-sterilized) reduce cleaning validation.
User case – mAb concentration (December 2025): Bioprocess lab (US) performs concentration (10x) of monoclonal antibody (cell culture supernatant, 5L). Benchtop TFF (Sartorius Sartoflow Advanced, 50kDa MWCO, 0.1 m² cassette). TMP 1.5 bar, crossflow 5 L/min, 2 hours. Final volume 0.5L. Assays: SDS-PAGE, SEC (size exclusion chromatography).
User case – viral vector diafiltration (January 2026): AAV manufacturing (Gene therapy, Europe) uses fully automatic benchtop TFF (Repligen KrosFlo) for buffer exchange (PBS). 500 mL AAV, 100kDa MWCO hollow fiber (retains AAV (25nm)), 6 diavolumes. Permeate contains impurities. Automated data logging.
3. Technical Challenges
Membrane fouling and cleaning – TFF membrane fouling reduces flux, increases TMP. Cleaning protocols (NaOH, EDTA, protease). Single-use disposable flow paths (pre-sterilized) avoid cleaning validation.
Process transferability to manufacturing scale – Scale-up from benchtop to pilot to manufacturing (constant linear flow velocity, TMP). Hollow fiber vs cassette.
Technical difficulty – shear sensitivity of large molecules: AAV, lentivirus, exosomes (shear sensitive). Low-shear pump (peristaltic vs diaphragm). Membrane selection.
Technical development (October 2025): Repligen introduced XCell ATF benchtop system with alternating tangential flow (ATF, diaphragm pump) low shear for cell retention (perfusion culture). Target N-1 seed.
4. Competitive Landscape
Key players include: Sartorius (Germany – Sartoflow, Slice), SOLARIS BIOTECH (Spain), Repligen (US – KrosFlo, XCell ATF), Sterlitech (US – CF, CF042), Optimus Instruments (India), Tezalon (India), Bailinke Pharmaceutical Technology (Shanghai), H&E Co., Ltd. (China), Rongjie Biotechnology (Suzhou), Beijing Huo’ersi Biological Technology. Sartorius, Repligen, SOLARIS leaders.
Regional dynamics: Europe (Sartorius, SOLARIS). North America (Repligen, Sterlitech). India (Optimus, Tezalon). China (Bailinke, H&E, Rongjie, Huo’ersi) domestic.
5. Outlook
Benchtop TFF system market will grow at 8.0% CAGR to US$413 million by 2032, driven by biologics process development, gene therapy, and pilot-scale GMP manufacturing. Technology trends: fully automated, GMP-ready, single-use disposable flow paths, low-shear ATF, and integration with PAT (process analytical technology). Asia-Pacific growth 10-12% CAGR. Greater adoption in CGT (cell and gene therapy) manufacturing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
